Exchange: NYSE·Updated 07:34 PM EDT
News
all
press releases
If You Invested $100 In Charles River Stock 15 Years Ago, You Would Have This Much Today
Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 2.07% on an annualized basis producing an average annual return of 15.79%. Currently, Charles River has a market capitalization of $14.32read more...
Benzinga
More News
International Markets and Charles River (CRL): A Deep Dive for Investors
Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Zacks
ICLR Jumps 33.2% in Three Months as Recovery Expectations Strengthen
ICON's 33.2% rally is backed by stronger proposal flow, bookings and backlog, but weaker earnings and margins cloud the recovery.
Zacks
CRL Q2 Earnings and Revenues Top, '26 View Up, Stock Up in Pre-Market
Charles River beats Q2 earnings and revenue estimates, raises 2026 outlook and gains 7.9% in pre-market trading.
Zacks
Has Charles River Laboratories International (CRL) Outpaced Other Medical Stocks This Year?
Here is how Charles River Laboratories (CRL) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.
Zacks
Charles River (CRL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates
Charles River (CRL) delivered earnings and revenue surprises of +11.03% and +3.43%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Charles River Laboratories International Q2 26 Earnings Conference Call At 9:00 AM ET
(RTTNews) - Charles River Laboratories International Inc. (CRL) will host a conference call at 9:00 AM ET on August 5, 2026, to discuss Q2 26 earnings results...
Nasdaq News: Markets
Charles River Laboratories Announces Second-Quarter 2026 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter ended June 27, 2026. Key Highlights Reports second-quarter revenue of $1.00 billion, GAAP loss per share of $(0.03), and non-GAAP earnings per share of $3.02. Organic revenue growth of 0.1...
Business Wire
Can These 3 MedTech Stocks Hit Targets This Earnings Season?
Can Zimmer Biomet, Charles River Laboratories and Bio-Techne meet earnings expectations? See the MedTech trends and company-specific drivers in focus.
Zacks

Advertisement|Remove ads.